MAPT and Alzheimer disease: MBwhich is known to inhibit tau aggregation and enhance mitochondrial respiration [60, 65, 66] has gained interest for potential AD therapy; however the later-phase clinical trials revealed dose-dependent toxicity and limited brain bioavailability, constraining its translational potential [17, 41, 61, 67, 68].Therefore, co-encapsulation of MB with MO in a nanocarrier system offers a rational strategy for a possible therapeutic synergy, via improving the pharmacokinetic stability, and potentiate disease-modifying efficacy.